Business Insider
My Markets Watchlist
Markets Stocks

Amgen Inc. Stock , AMGN

289.97 -0.38 -0.13%
03:59:59 PM EDT 6/9/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 06/06/2025 the closing price of the Amgen Inc. share was $290.35 on BTT. Compared to the opening price on Friday 06/06/2025 on BTT of $290.30, this is a gain of 0.02%. Amgen Inc.'s market capitalization is $128.40 B by 537.71 M shares outstanding.
Is Amgen stock a Buy, Sell or Hold? Amgen stock has received a consensus rating of buy. The average rating score is Baa1 and is based on 26 buy ratings, 22 hold ratings, and 3 sell ratings.
What was the 52-week low for Amgen stock? The low in the last 52 weeks of Amgen stock was 253.38. According to the current price, Amgen is 114.44% away from the 52-week low.
What was the 52-week high for Amgen stock? The high in the last 52 weeks of Amgen stock was 346.67. According to the current price, Amgen is 83.64% away from the 52-week high.
What are analysts forecasts for Amgen stock? The 51 analysts offering price forecasts for Amgen have a median target of 297.53, with a high estimate of 355.00 and a low estimate of 200.00. The median estimate represents a 97.46 difference from the last price of 289.97.

Amgen Stock Snapshot

288.38
Bid
1.00
Bid Size
293.16
Ask
4.00
Ask Size
6/9/2025
Date
3:59 PM
Time
0.00
Volume
290.35
Prev. Close
0.00
Open
156.02 B
Market Cap in USD
537.71 M
Number of Shares
537.71 M
Total Number of Shares
253.38
52 Week Low
346.67
52 Week High
289.97
9.00
Dividend in USD
3.45
Dividend Yield
34.48
P/E Ratio
99.78
Free Float in %
7.56
EPS in USD
10.95
Book Value per Share in USD
21.24
Cash Flow per Share in USD

Historical Prices for Amgen

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Amgen Analyst Data

Total Analysts: 51
Buy Ratings: 26 Neutral Ratings: 22 Sell Ratings: 3
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 200.00 Median: 297.53 Highest: 355.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Amgen Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/20/25 Guggenheim
Maintained Hold $288
05/16/25 Piper Sandler
Maintained Buy $328
05/07/25 Mizuho
Maintained Hold $280
05/02/25 UBS
Maintained Hold $315
05/02/25 RBC Capital Markets
Maintained Buy $320
04/14/25 UBS
Maintained Hold $319
04/09/25 Morgan Stanley
Maintained Hold $330
03/05/25 Bank of America Merrill Lynch
Maintained Sell $294
02/10/25 Piper Sandler
Maintained Buy $329
02/06/25 Bank of America Merrill Lynch
Maintained Sell $275
01/28/25 Citigroup Corp.
Maintained Hold $295
01/24/25 RBC Capital Markets
Maintained Buy $324
07/11/24 Morgan Stanley
Maintained Hold $303
06/27/24 Argus Research Company
Maintained Buy $340
06/14/24 RBC Capital Markets
Maintained Buy $332
05/09/24 Mizuho
Maintained Hold $235
05/03/24 RBC Capital Markets
Maintained Buy $328
05/03/24 Morgan Stanley
Maintained Hold $310
05/03/24 UBS
Maintained Hold $307
05/03/24 William Blair
Upgraded to Buy
05/03/24 BMO Capital Markets
Maintained Buy $355
05/03/24 Barclays Capital
Upgraded to Hold $300
04/03/24 RBC Capital Markets
Maintained Buy $329
03/28/24 Raymond James Financial, Inc.
Maintained Hold
02/07/24 RBC Capital Markets
Maintained Buy $329
02/07/24 Goldman Sachs
Maintained Buy $350
02/07/24 Morgan Stanley
Maintained Hold $278
02/01/24 Oppenheimer & Co. Inc.
Maintained Buy $350
01/29/24 UBS
Maintained Hold $314
12/21/23 Daiwa Securities
Upgraded to Buy $320
12/19/23 BMO Capital Markets
Upgraded to Buy $326
12/12/23 RBC Capital Markets
Upgraded to Buy $300
11/09/23 Deutsche Bank
Maintained Hold $240
11/02/23 UBS
Maintained Hold $268
11/01/23 RBC Capital Markets
Maintained Hold $256
11/01/23 Morgan Stanley
Maintained Hold $291
10/25/23 Oppenheimer & Co. Inc.
Maintained Buy $310
10/20/23 Oppenheimer & Co. Inc.
Maintained Buy $300
10/20/23 J.P. Morgan
Maintained Hold $270
10/17/23 Argus Research Company
Maintained Buy $310
10/17/23 Morgan Stanley
Maintained Hold $300
10/12/23 Jefferies & Company Inc.
Maintained Buy $310
10/11/23 Bank of America Merrill Lynch
Maintained Hold $290
10/09/23 Oppenheimer & Co. Inc.
Maintained Buy $290
09/18/23 Argus Research Company
Maintained Buy $280
09/06/23 HSBC
Maintained Buy $320
08/14/23 Jefferies & Company Inc.
Maintained Buy $310
08/14/23 Mizuho
Maintained Hold $223
08/04/23 RBC Capital Markets
Maintained Hold $253
07/25/23 Oppenheimer & Co. Inc.
Maintained Buy $280

Amgen Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 35,279 35,936 37,096 37,497 38,411
Dividend 9.65 10.23 10.63 12.14 13.01
Dividend Yield (in %) 3.32 % 3.52 % 3.66 % 4.18 % 4.48 %
EPS 20.86 21.52 22.59 23.00 23.97
P/E Ratio 13.91 13.49 12.85 12.63 12.11
EBIT 15,593 15,843 16,271 16,334 16,718
EBITDA 17,170 17,295 17,695 18,849 18,555
Net Profit 11,300 11,634 12,215 12,424 12,926
Net Profit Adjusted 11,300 11,634 12,215 12,424 12,926
Pre-Tax Profit 13,302 13,689 14,417 14,677 15,331
Pre-Tax Profit Reported 9,277 11,311 13,988 16,723 17,938
EPS (Non-GAAP) ex. SOE 20.48 21.67 21.77 22.16 23.42
EPS (GAAP) 13.43 14.30 - 19.55 22.50
Gross Income 27,923 28,636 29,828 30,918 31,642
Cash Flow from Investing -2,157 -2,004 -1,839 -2,054 -2,031
Cash Flow from Operations 10,996 13,731 14,204 14,341 14,576
Cash Flow from Financing -7,724 -9,722 -9,283 -9,930 -10,384
Cash Flow per Share 23.90 26.73 27.19 30.78 30.95
Free Cash Flow 10,015 13,179 13,563 12,172 13,234
Free Cash Flow per Share - - - - -
Book Value per Share 16.94 23.37 31.92 50.31 66.08
Net Debt 43,942 37,978 32,259 14,137 4,070
Research & Development Exp. 6,881 6,934 7,123 7,222 7,413
Capital Expenditure 2,133 1,492 1,362 1,443 1,425
Selling, General & Admin. Exp. 6,634 6,764 6,936 7,176 7,400
Shareholder’s Equity 9,810 14,357 18,959 27,572 34,091
Total Assets 92,659 94,382 97,592 101,581 104,909
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 23 23 28 28
Average Estimate - 5.234 USD 5.354 USD 20.854 USD 21.522 USD
Year Ago - 1.389 USD 5.270 USD 7.616 USD -
Publish Date - 8/5/2025 10/29/2025 - -
Revenue Estimates
No. of Analysts - 21 21 27 27
Average Estimate - 8,876 USD 8,911 USD 35,272 USD 35,904 USD
Year Ago - 8,333 USD 8,458 USD 33,232 USD -
Publish Date - 8/5/2025 10/29/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 33,232.00 28,010.00 26,092.00 25,987.00 25,246.00 23,261.00 23,768.00
Change of sales in % 18.64 7.35 0.40 2.94 8.53 -2.13 4.32
Gross profit on sales 21,333.00 20,301.00 19,686.00 19,533.00 19,087.00 18,905.00 19,667.00
Gross profit on sales change in % 5.08 3.12 0.78 2.34 0.96 -3.87 5.09
Operating income 8,313.00 9,177.00 9,335.00 9,152.00 8,961.00 9,573.00 10,326.00
Operating income change in % -9.41 -1.69 2.00 2.13 -6.39 -7.29 3.07
Income before tax 4,609.00 7,855.00 7,346.00 6,701.00 8,133.00 9,138.00 9,545.00
Income before tax change in % -41.32 6.93 9.63 -17.61 -11.00 -4.26 -0.54
Income after tax 4,090.00 6,717.00 6,552.00 5,893.00 7,264.00 7,842.00 8,394.00
Income after tax change in % -39.11 2.52 11.18 -18.87 -7.37 -6.58 324.15

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 85,962.00 90,922.00 61,460.00 54,465.00 53,539.00 50,034.00 53,916.00
Long-term liabilities per share 117.09 135.47 85.72 75.73 72.43 62.90 64.21
Equity 5,877.00 6,232.00 3,661.00 6,700.00 9,409.00 9,673.00 12,500.00
Equity change in % -5.70 70.23 -45.36 -28.79 -2.73 -22.62 -50.48
Balance sheet total 91,839.00 97,154.00 65,121.00 61,165.00 62,948.00 59,707.00 66,416.00
Balance sheet total change in % -5.47 49.19 6.47 -2.83 5.43 -10.10 -16.93

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 61.43 52.06 48.23 45.35 42.79 38.20 35.74
P/E ratio (year end quote, basic EPS) 34.48 23.07 21.69 21.87 18.67 18.72 15.42
P/E ratio (year end quote, diluted EPS) 34.48 23.07 21.69 21.87 18.67 18.72 15.42
Dividend yield in % 3.45 2.96 2.95 3.13 2.78 2.41 2.71
Equity ratio in % 6.40 6.41 5.62 10.95 14.95 16.20 18.82
Debt ratio in % 93.60 93.59 94.38 89.05 85.05 83.80 81.18

Amgen Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Drake Michael V 05/22/2025 809.00 4,546.60 n/a Buy No
HOLLEY CHARLES M 05/22/2025 809.00 11,237.17 n/a Buy No
ECKERT ROBERT 05/22/2025 809.00 25,027.00 n/a Buy No
ISHRAK OMAR 05/22/2025 809.00 6,084.50 n/a Buy No
Kullman Ellen Jamison 05/22/2025 809.00 13,466.98 n/a Buy No
Druker Brian 05/22/2025 809.00 7,569.00 n/a Buy No
Garland Greg C. 05/22/2025 809.00 13,183.00 n/a Buy No
Jacks Tyler 05/22/2025 809.00 17,193.00 n/a Buy No
MILES AMY E 05/22/2025 809.00 4,842.00 n/a Buy No
Austin Wanda M 05/22/2025 809.00 7,353.00 n/a Buy No
Klotman Mary E. 05/22/2025 809.00 1,528.00 n/a Buy No
Drake Michael V 05/05/2025 129.42 3,737.60 n/a Buy No
Bradway Robert A 05/05/2025 13,311.00 413,499.00 n/a Buy No
Busch Matthew C. 05/05/2025 554.00 4,588.00 n/a Buy No
Miller Derek 05/05/2025 961.00 10,189.00 n/a Buy No
Grygiel Nancy A. 05/05/2025 591.00 8,463.00 n/a Buy No
Graham Jonathan P 05/05/2025 3,180.00 33,517.00 n/a Buy No
REESE DAVID M 05/05/2025 3,549.00 42,116.00 n/a Buy No
Bradner James E. 05/05/2025 3,549.00 29,753.00 n/a Buy No
Gordon Murdo 05/05/2025 3,919.00 49,985.00 n/a Buy No
ISHRAK OMAR 05/05/2025 129.42 5,275.50 n/a Buy No
Griffith Peter H. 05/05/2025 3,919.00 42,246.00 n/a Buy No
Khosla Rachna 05/05/2025 610.00 9,662.00 n/a Buy No
Santos Esteban 05/05/2025 3,327.00 76,367.00 n/a Buy No
Bradway Robert A 05/01/2025 2,352.00 400,188.00 283.78 Sell No

Amgen Dividend Calendar

Date Name Dividend *yield Currency
2024 Amgen Inc. 9.00 3.45 USD
2023 Amgen Inc. 8.52 2.96 USD
2022 Amgen Inc. 7.76 2.95 USD
2021 Amgen Inc. 7.04 3.13 USD
2020 Amgen Inc. 6.40 2.78 USD
2019 Amgen Inc. 5.80 2.41 USD
2018 Amgen Inc. 5.28 2.71 USD
2017 Amgen Inc. 4.60 2.65 USD
2016 Amgen Inc. 4.00 2.74 USD
2015 Amgen Inc. 3.16 1.95 USD
2014 Amgen Inc. 2.44 1.53 USD
2013 Amgen Inc. 1.88 1.65 USD
2012 Amgen Inc. 1.44 1.67 USD
2011 Amgen Inc. 0.56 0.87 USD
2010 Amgen Inc. 0.00 0.00 USD
2009 Amgen Inc. 0.00 0.00 USD
2008 Amgen Inc. 0.00 0.00 USD
2007 Amgen Inc. 0.00 0.00 USD
2006 Amgen Inc. 0.00 0.00 USD
2005 Amgen Inc. 0.00 0.00 USD
2004 Amgen Inc. 0.00 0.00 USD
2003 Amgen Inc. 0.00 0.00 USD
2002 Amgen Inc. 0.00 0.00 USD
2001 Amgen Inc. 0.00 0.00 USD
2000 Amgen Inc. 0.00 0.00 USD
1999 Amgen Inc. 0.00 0.00 USD
*Yield of the Respective Date

Amgen Calendar

Event Estimate Info Date
Earnings Report 5.234 USD Q2 2025 Earnings Release 08/05/2025
Earnings Report 5.354 USD Q3 2025 Earnings Release 10/29/2025
Earnings Report 5.316 USD Q4 2025 Earnings Release 02/03/2026
Earnings Report 4.856 USD Q1 2026 Earnings Release 04/30/2026

Amgen Past Events

Event Actual EPS Info Date
Annual General Meeting 7.560 USD Annual General Meeting 05/23/2025
Earnings Report 3.200 USD Q1 2025 Earnings Release 05/01/2025
Earnings Report 1.160 USD Q4 2024 Earnings Release 02/04/2025
Earnings Report 5.220 USD Q3 2024 Earnings Release 10/30/2024
Earnings Report 1.380 USD Q2 2024 Earnings Release 08/06/2024
Annual General Meeting 12.490 USD Annual General Meeting 05/31/2024
Earnings Report -0.210 USD Q1 2024 Earnings Release 05/02/2024
Earnings Report 1.420 USD Q4 2023 Earnings Release 02/06/2024
Earnings Report 3.220 USD Q3 2023 Earnings Release 10/31/2023
Earnings Report 2.570 USD Q2 2023 Earnings Release 08/03/2023
Annual General Meeting 12.110 USD Annual General Meeting 05/19/2023
Earnings Report 5.280 USD Q1 2023 Earnings Release 04/27/2023
Earnings Report 3.000 USD Q4 2022 Earnings Release 01/31/2023
Earnings Report 3.980 USD Q3 2022 Earnings Release 11/03/2022
Earnings Report 2.450 USD Q2 2022 Earnings Release 08/04/2022
Annual General Meeting 10.280 USD Annual General Meeting 05/17/2022
Earnings Report 2.680 USD Q1 2022 Earnings Release 04/27/2022
Earnings Report 3.360 USD Q4 2021 Earnings Release 02/07/2022

Amgen Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr. , Franklin Pitcher Johnson, Jr. , George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. .

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
4
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Amgen Management

Name Job
Robert A. Bradway Chairman, President & Chief Executive Officer
Matthew C. Busch Chief Accounting Officer & Vice President-Finance
Linda H. Louie Chief Accounting Officer & Vice President-Finance
Nancy A. Grygiel Chief Compliance Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
Derek Miller Chief Human Resources Officer
Scott Skellenger Chief Information Officer & Senior VP
Paul Burton Chief Medical Officer & Senior Vice President
Jackie Elbonne Chief Quality Officer & Senior Vice President
Howard Y. Chang Chief Scientific Officer & SVP-Global Research
David M. Reese Chief Technology Officer & Executive VP
Murdo J. Gordon EVP-Global Commercial Operations
Susan Sweeney Executive VP-Obesity & Related Conditions
James E. Bradner Executive VP-Research & Development
Esteban Santos Executive Vice President-Operations
Mary Earley Klotman Independent Director
Michael V. Drake Independent Director
Tyler E. Jacks Independent Director
Ellen Jamison Kullman Independent Director
Amy E. Miles Independent Director
Greg C. Garland Independent Director
Omar Syed Ishrak Independent Director
Charles M. Holley Independent Director
Wanda M. Austin Independent Director
Brian J. Druker Independent Director
Robert A. Eckert Lead Independent Director
Yang Li Scientific Director
Jonathan P. Graham Secretary, Executive VP & General Counsel
Greg Portner Senior VP-Global Government Affairs & Policy
Mark J. Taisey Senior VP-Global Regulatory Affairs & Strategy
Jean-Charles Soria Senior VP-Research & Development
Rachna Khosla Senior Vice President-Business Development
Sam Guhan Senior Vice President-Global Engineering
Kave Niksefat Senior Vice President-Global Marketing & Access
Darryl Sleep Senior Vice President-Global Medical
Justin Gary Claeys Vice President-Investor Relations